Lemzoparlimab clinical trials
Also written TJ011133.
How each study uses lemzoparlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
TJ Biopharma Co., Ltd. (2) · AbbVie (2) · I-Mab Biopharma US Limited (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lemzoparlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)TerminatedPhase 3TJ Biopharma Co., Ltd.NCT05709093Written as Lemzoparlimab+Azacitidine (AZA)How we know
- Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedPhase 1I-Mab Biopharma US LimitedNCT03934814Written as TJ011133How we know
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedPhase 1/2TJ Biopharma Co., Ltd.NCT04202003Written as TJ011133How we know
- Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedPhase 1AbbVieNCT04912063Written as LemzoparlimabHow we know
- Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaTerminatedPhase 1AbbVieNCT04895410Written as LemzoparlimabHow we know
Codes
What other systems call lemzoparlimab · ClinicalTrials.gg INT014196
- UNII (FDA) 0H2XLR2IKWLEMZOPARLIMABOne source FDA
- NCI Thesaurus C163977LemzoparlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0H2XLR2IKW | LEMZOPARLIMAB | One source FDA |
| NCI Thesaurus | C163977 | Lemzoparlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.